bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Time to Buy?
by Danessa Lincoln · The Markets DailybioMerieux (OTCMKTS:BMXMF – Get Free Report)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $77.93, but opened at $82.78. bioMerieux shares last traded at $82.78, with a volume of 259 shares.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Piper Sandler assumed coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating for the company. Morgan Stanley cut shares of bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Finally, UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Five equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.
Check Out Our Latest Research Report on BMXMF
bioMerieux Stock Performance
The stock has a fifty day moving average of $82.43 and a 200-day moving average of $104.16. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.
bioMerieux Company Profile
bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.